Annual report [Section 13 and 15(d), not S-K Item 405]

Commitments and Contingencies - Additional Information (Details)

v3.25.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Commitments and Contingencies [Line Items]    
Terms agreement description Under the August 2023 work orders, WuXi converted the Company’s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company’s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company’s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to WuXi to extend the initial term of the WuXi Agreement by 18 months through August 2026.  
Research and development expense $ 97,203 $ 55,424
Rese-Cel and MuSK-CAART [Member]    
Commitments and Contingencies [Line Items]    
Early termination fee $ 1,080  
Wuxi Agreement    
Commitments and Contingencies [Line Items]    
Lease expiration month 18 months  
Early termination fee $ 1,500  
Lonza Agreement [Member]    
Commitments and Contingencies [Line Items]    
Payment term 12 months  
liability related to agreement $ 16,000